Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Centessa Pharmaceuticals plc

< Previous 1 2 Next >
News headline image
Centessa Pharmaceuticals to Participate in TD Cowen’s 44th Annual Health Care Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at the 17th Annual Congress of the European Association for Haemophilia and
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Present at the 42ⁿᵈ Annual J.P. Morgan Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces New Data from an Additional 52-Weeks of Continuous Treatment from Third Year (Part 5) of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Present Additional 52-Weeks of Continuous Treatment Data from Third Year of Ongoing Phase 2a Study of SerpinPC for the Treatment of Hemophilia at American Society of Hematology (ASH) Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-3 Study Evaluating SerpinPC for the Treatment of Hemophilia B with Inhibitors
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Preclinical Data Supporting ORX750’s Potential as a Best-in-Class Oral OX2R Agonist for the Treatment of Narcolepsy and Other Sleep-Wake Disorders
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Additions to Senior Leadership Team
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Present Preclinical Data for Novel Orexin Receptor 2 (OX2R) Agonist at World Sleep Congress
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Second Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Dosing of First Subject in Registrational PRESent-2 Study Evaluating SerpinPC for the Treatment of Hemophilia B without Inhibitors
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Receives Fast Track Designation from the U.S. FDA for SerpinPC for Hemophilia B
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the First Quarter of 2023
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Recent Business Progress and Financial Results for the Fourth Quarter and Full-Year 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Addition of Patrick Yue, MD, as Senior Vice President of Clinical Development, Innovative Medicines
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Present Additional Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia at the 16th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD)
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Presentation at the SVB Securities Global Biopharma Conference
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces FDA Clearance of IND Application for Phase 1/2a Clinical Trial of LB101, First LockBody® Candidate, for Solid Tumors
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces Additional 18-Months of Continued Treatment Data from Open-Label Extension (OLE) of Phase 2a Study of SerpinPC for Hemophilia
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Announces New Chief People Officer Karen Anderson
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals Reports Financial Results and Business Highlights for the Third Quarter of 2022
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Present Additional 18-Months of Continued Treatment Data with SerpinPC from Open-Label Extension of Phase 2a Study at 64th ASH Annual Meeting
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Pharmaceuticals to Participate in Upcoming Investor Conferences
From Centessa Pharmaceuticals plc
Via GlobeNewswire
Tickers CNTA
News headline image
Centessa Announces Pricing of Initial Public Offering
From Centessa Pharmaceuticals plc
Via Business Wire
Tickers CNTA
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.